Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 22Active not recruiting 9Withdrawn 5Terminated 3Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Myeloid 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Interventional × navitoclax × Clear all
NCT03366103 2023-10-17

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Terminated
15 enrolled 14 charts
Thoracic

Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT04480086 2023-08-29

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

AbbVie

Phase 1 Terminated
1 enrolled
Myeloid

Neoplasms, Primary Myelofibrosis

NCT01828476 2017-05-04

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Rutgers, The State University of New Jersey

Phase 2 Terminated
13 enrolled 5 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡